OBJECTIVE: Clinical estimation of fetal weight (EFW) prior to delivery is a routine obstetric practice. The effect of maternal height on the accuracy of EFW is unclear. The aim of this study was to examine the accuracy of clinical EFW according to maternal height. STUDY DESIGN: This retrospective cohort study included women with singleton pregnancies at term (37 weeks) who delivered in our institution between January 2015 and June 2018 and for whom maternal height, pre-pregnancy and current weight and clinical EFW were recorded before delivery. We assessed the magnitude of clinical EFW error according to maternal height. An absolute error was calculated as follow: [(actual birthweight-clinical EFW)/actual birthweight]x100. An under-or over-estimation of FW were defined as errors of 10% below or above the actual birthweight, respectively. The absolute error and the distribution of accurate (-10% to +10%) under-and over-estimation of FW were compared across maternal height percentiles [<10 th , 10-90 th , >90 th ] and BMI (kg/ m2) categories (<18.5, 18.5-24.9, 25-29.9, >30). RESULTS: A total of 12,902 women met the inclusion criteria. The 10 th and 90 th height centiles of this cohort were 155cm and 170cm, respectively. The rate of accurate, under-and over-estimation of FW in the total cohort were 70.5%, 18% and 11.6%, respectively. The distributions across maternal height centile and BMI categories are presented in Table 1 .Among women in the >90 th height centile, the rate of under-estimation was higher than the rate of over-estimation (23.6% vs. 6.7%, p<0.001) while among women in the <10 th height percentile the opposite was notices (under-estimation 13.9% vs. over-estimation 19.2%, p<0.001). The CS rate of the entire cohort was 16.3%. Interestingly, although the CS rate was significantly higher in the over-estimation compared to the under-estimation group (24.5% vs. 12.5%, p<0.001), the mean birthweight was significantly lower in the over-compared to the under-estimation group (2830 gr vs 3772 gr, p<0.001). CONCLUSION: At the extremes of maternal heights percentiles, clinical EFW is more challenging, with a higher rate of under-estimation in tall women and a higher rate of over-estimation in short women.-Over-estimtion of FW has a negative impact on the CS rate.This limitation of clinical EFW at the extremes of the maternal heights should be acknowledge and in these women additional tools (i.e., sonographic EFW) should be considered for clinical making decisions before delivery. OBJECTIVE: Risk of stillbirth in women with chronic hypertension (CHTN) is 6-25 per 1,000, approximately 2-fold higher than women without CHTN. ACOG recommends initiation of antepartum fetal surveillance (ANFS) no earlier than 32 weeks' gestation for most women with CHTN. We sought to quantify the cumulative proportion of stillbirths in women with CHTN by gestational age (GA) and to identify risk factors associated with earlier stillbirth (<32 wks) in this population. STUDY DESIGN: Population-based retrospective cohort study of all stillbirths in the U.S. during the year of 2014. Frequency of stillbirth in women who were antenatally diagnosed (non-laboring) with fetal demise were stratified by GA, from 20 to 44 weeks, according to CHTN status. Cause of fetal death was obtained from ICD-10 codes. Maternal and obstetric characteristics were compared between those with and without CHTN and then subsequently for those with early (<32 weeks) stillbirth vs late (32 weeks) stillbirth among women with CHTN. Multivariate logistic regression estimated the relative association between CHTN and various maternal, obstetric, and fetal factors. RESULTS: There were 14,954 non-laboring women diagnosed with antepartum (non-laboring) stillbirth during 2014 in the US in which CHTN status was recorded. Of those, 14,954 stillbirths, 793 (5.3%) women had CHTN. Median GA of antepartum stillbirth diagnosis was 27 (IQR 23,34) weeks vs 29 (IQR (23,36) weeks (p<0.001) between women with and without CHTN, respectively. The cumulative rates of stillbirth by GA among women with CHTN where cause of fetal death was attributed to "maternal hypertensive disorder" were 34. 1, 59.9, 75.4, 82.3, and 90.1% at 24, 28, 32, 34, and 36 weeks' gestation, respectively. Women with CHTN had higher rates of obesity, diabetes, and stillbirth < 32 wks (67.0 vs 58.7%, p<0.001; aRR 1.9, CI 1.5-2.5) compared to women without CHTN. Factors associated with early stillbirth among women with CHTN included lagging fetal growth as evidenced by small for gestational age (SGA <10 th %) birthweight (aRR 1.6, CI 1.1-2.3), Black race (aRR 1.8, CI 1.3-2.6), and primiparity (aRR 1.4, CI 1.0-2.1). CONCLUSION: Stillbirth occurs at an earlier GA among women with CHTN compared to those without. More than 50% of stillbirths attributed to maternal hypertensive disorders occurred before 27 wks and over 70% occurred before 32 wks. Current ANFS guidelines may fail to prevent the majority of antepartum stillbirths among women with CHTN.
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OBJECTIVE: Risk of stillbirth in women with pregestational diabetes (PGDM) is approximately 2-fold higher than the non-diabetic pregnant population. ACOG recommends initiation of antepartum fetal surveillance (ANFS) between 32-34 weeks' gestation for most patients with PGDM. We sought toidentify maternal and fetal factors associated with earlier stillbirth in women with PGDM and to compare the cumulative rates of stillbirths by GA in women with PGDM and other factors associated with earlier stillbirth in this population. STUDY DESIGN: Population-based retrospective cohort study of all stillbirths in the U.S. during the year 2014. Frequency of stillbirths in women who were diagnosed antepartum (non-laboring) were stratified by GA, 20-44 weeks, according to PGDM status. Cause of fetal death was obtained from ICD-10 codes. Maternal, obstetric, and fetal characteristics in women with PGDM were compared between those with early ( 32 weeks) vs late (>32 weeks) stillbirth. Multivariate logistic regression estimated the relative association of various maternal, obstetric, and fetal factors on risk for early stillbirth among women with PGDM. RESULTS: Of 14,362 women diagnosed with antepartum (nonlaboring) stillbirth during 2014 in the US, 591 (4.1%) women had PGDM. The median GA at diagnosis was 33 (IQR 26,37) weeks with nearly half (47.2%) occurring 32 wksand 52.8% after 32 wks. The cumulative rates of stillbirth by GA among women with PGDM were 22.6, 35.0, 47.2, and 55.2% at 24, 28, 32, 34 weeks' gestation respectively. Factors associated with early stillbirth among women with PGDM included lagging fetal growth as evidenced by small for gestational age (SGA<10 th %) birthweight (aRR 2.6, CI 1.6-4.1) and chronic HTN (aRR 1.7, CI 1.0-2.9). Over 50% of stillbirths occurred before 34 wks in women with PGDM, before 31 wks in women with PGDM plus chronic HTN, and before 30 weeks in women with PGDM plus SGA birthweight. Despite a median occurrence of stillbirth at 33 wks among women with PGDM, 12.9% of stillbirths attributed to "maternal diabetes" occurred between 28-32 weeks' gestation; when ANFS is typically not recommended for this population. CONCLUSION: Stillbirth occurs at earlier GA among women with PGDM and additional risk factors including fetal growth restriction and chronic HTN despite current guidelines recommending ANFS at 32-34 weeks. Recommendations to initiate ANFS between 32-34 weeks may fail to prevent a significant proportion of stillbirths in this population.
